To explore the possibility of CXCR4 predicting response to immunotherapy in NSCLC patients, we included PD1 (PDCD1), PDL1 (CD274), CTLA4, LAG3, GAL9 (LGALS9), TIM-3 (HAVCR2), TIGIT and PD-1LG2 (PDCD1LG2) as immune checkpoint-related candidate genes to evaluate their relationship with CXCR4. This evidence concerns the gene PDCD1LG2 and non-small cell lung carcinoma.